TY - JOUR
T1 - Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry
AU - Brewster, Abenaa M.
AU - Chavez-MacGregor, Mariana
AU - Brown, Powel
N1 - Funding Information:
We thank Erica Goodoff for providing editorial assistance. AMB is supported by a US National Institute of Health (NIH) grant (1R01CA172511-01). PB is supported by NIH grants (5P30 CA016672-38; N01-CN-2012-00034, and N01-CN-35159). These funding sources had no role in the planning and writing of the review.
Publisher Copyright:
© 2014 Elsevier Ltd.
PY - 2014
Y1 - 2014
N2 - Breast cancer incidence is increasing worldwide, and breast cancer-related mortality is highest in women of African ancestry, who are more likely to have basal-like or triple-negative breast cancer (TNBC) than are women of European ancestry. Identification of cultural, epidemiological, and genetic risk factors that predispose women of African ancestry to TNBC is an active area of research. Despite the aggressive behaviour of TNBC, achievement of a pathological complete response with chemotherapy is associated with good long-term survival outcomes, and sensitivity to chemotherapy does not seem to differ according to ethnic origin. Discovery of the molecular signalling molecules that define TNBC heterogeneity has led to the development of targeted agents such as inhibitors of poly (ADP-ribose) polymerase-1 and mTOR and immunomodulatory drugs that are in the early stages of clinical testing. First, we summarise the existing published work on the differences reported on the epidemiology, biology, and response to systemic treatment of TNBC between women of African ancestry and white women, and identify some gaps in knowledge. Second, we review the opportunities for development of new therapeutic agents in view of the potential high clinical relevance for patients with TNBC irrespective of race or ethnic origin.
AB - Breast cancer incidence is increasing worldwide, and breast cancer-related mortality is highest in women of African ancestry, who are more likely to have basal-like or triple-negative breast cancer (TNBC) than are women of European ancestry. Identification of cultural, epidemiological, and genetic risk factors that predispose women of African ancestry to TNBC is an active area of research. Despite the aggressive behaviour of TNBC, achievement of a pathological complete response with chemotherapy is associated with good long-term survival outcomes, and sensitivity to chemotherapy does not seem to differ according to ethnic origin. Discovery of the molecular signalling molecules that define TNBC heterogeneity has led to the development of targeted agents such as inhibitors of poly (ADP-ribose) polymerase-1 and mTOR and immunomodulatory drugs that are in the early stages of clinical testing. First, we summarise the existing published work on the differences reported on the epidemiology, biology, and response to systemic treatment of TNBC between women of African ancestry and white women, and identify some gaps in knowledge. Second, we review the opportunities for development of new therapeutic agents in view of the potential high clinical relevance for patients with TNBC irrespective of race or ethnic origin.
UR - http://www.scopus.com/inward/record.url?scp=84925231928&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925231928&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(14)70364-X
DO - 10.1016/S1470-2045(14)70364-X
M3 - Review article
C2 - 25456381
AN - SCOPUS:84925231928
SN - 1470-2045
VL - 15
SP - e625-e634
JO - The lancet oncology
JF - The lancet oncology
IS - 13
ER -